NAD+ for Sale: Food-Grade Powder in a Sterile IV Bag

A product page is a document, and in this market it is usually the only document you get. Everything you can know about the material before it arrives is on it, or conspicuously missing from it, and the missing parts are more informative than the present ones. This page is about reading one properly.

It matters more for NAD+ than for the peptides we normally cover, and there is a specific reason. NAD+ is a coenzyme manufactured at industrial scale for several markets, only one of which is injection. Powder that is entirely legitimate as a food ingredient can be sold on, relabelled and listed by somebody downstream who never says which market it was made for. The word that resolves that ambiguity is grade, and it is the word most listings leave out.

We link one supplier on this page and earn a commission on it, which our affiliate disclosure explains. The listing-reading method below is the same one we used on that supplier, and it is the reason we can tell you which lines it passes and which line you still have to check yourself.

FDA published a compounding risk notice, content current as of 30 October 2024, which says the agency "is aware of compounders using food-grade nicotinamide adenine dinucleotide (NAD+) sold by repackagers to make intravenous products." It adds that "ingredients identified as food grade are not suitable for compounding sterile drugs without appropriate processing, due to the high risk of contamination with microbes and endotoxins."

Then it reports what happened next. FDA "has received adverse event reports following use of NAD+ injectable drugs, including severe chills, shaking, vomiting and fatigue with some requiring medical treatment," and states those reactions are "consistent with excessive levels of endotoxins." The notice is short and worth reading in full.

Notice who that notice is addressed to. Not consumers browsing a research storefront: compounders, the licensed professionals whose job is sourcing. If food-grade material was reaching IV bags through people with a regulatory obligation to check, the odds that an anonymous listing has checked are not encouraging. A listing that says pharmaceutical grade in writing has made a claim you can hold it to. A listing that says nothing has left itself room.

So the first thing you look for is not the purity figure. It is a grade statement, and if there is not one, an email asking for it before you spend anything. The answer, or the absence of one, is the most useful data point available to you.

Peptide listings condition you to think in five and ten milligram vials. NAD+ listings are in hundreds of milligrams or whole grams, and readers who carry the peptide habit across misread the price by two orders of magnitude in one direction or the other.

Quote it per 100 mg. The listing we link is NAD+ 1,000 mg at $104.00, or $52.00 with the code PEPTIDEDECK, which is $5.20 per 100 mg. Expressed per milligram that becomes about five cents, a number that invites a comparison against peptide pricing that means nothing at all, because you are not buying the same kind of thing in the same kind of quantity.

The practical check on a listing is that the quantity, the unit and the container all agree. A page advertising a gram should tell you whether that is one vial or several, because a single one gram vial and ten hundred milligram vials are different products for handling purposes even at an identical price. Quantity tiers of three, five and ten units at the supplier we link take 3, 5 and 10 percent off the list price, and nothing published says those stack with the code, so read them as alternatives.

Most NAD+ listings publish a certificate of analysis, and most certificates cover identity and purity. High performance liquid chromatography reports how much of the sample is the compound. Mass spectrometry confirms it is the compound. Both are worth having and neither one measures bacterial endotoxin load, which is the specific hazard FDA's notice describes.

The test that does is bacterial endotoxins testing, commonly the LAL assay, reported in endotoxin units rather than as a percentage. FDA publishes a guidance on pyrogen and endotoxins testing if you want the framework behind it. A certificate showing 99 percent purity and no endotoxin line has answered a question you were not worried about.

Then two structural checks. Does the certificate carry a lot number that matches the number printed on the vial you receive, or is it a generic document about some batch, somewhere, once? And does it name the laboratory, or does the page just say third-party tested? A named lab can be searched. A phrase cannot.

The supplier we link states that two independent laboratories test every batch, which is more than this market usually offers. We have not run those analyses, and the check we would want you to run yourself is whether the endotoxin result is on the certificate attached to the lot in your hand.

This is where a careful reader can be caught out by something that looks like pedantry and is not. FDA's category list of bulk drug substances nominated for compounding under section 503A, updated 14 May 2026, includes nicotinamide adenine dinucleotide (NAD) in category 1, and nicotinamide adenine dinucleotide disodium reduced (NADH) in category 1 alongside it. Category 1 means FDA does not intend to take action against a compounder using the substance while its evaluation is pending, provided the guidance conditions are met. That is non-enforcement, not approval, and the list is explicitly under evaluation.

In the same document, beta-nicotinamide adenine dinucleotide disodium salt trihydrate sits in category 3, nominated without adequate supporting information for FDA to evaluate it. It reads like the same substance under a longer chemical name and it occupies a different position on FDA's own list. If a listing uses that name, you are not looking at the same entry, whatever the marketing copy says. Both lists are on FDA's bulk drug substances page.

The other name confusion is simpler. Plenty of pages selling NAD+ are selling precursors, usually nicotinamide mononucleotide or nicotinamide riboside, as oral supplements. Those are real products with their own separate history that we have not verified here, and they are a different purchase from a gram of powder. If the listing is a bottle of capsules, the comparison you were making has quietly changed subject.

A listing that expects you to handle material properly says how to store it. Lyophilized powder kept cold and dark, protected from moisture, is the normal instruction, and a page that says nothing about storage has told you the seller is not thinking past the checkout. Where a supplier ships from matters here for the same reason: material that has spent weeks in transit was not being temperature-monitored by anyone.

On format, expect a sealed vial of freeze-dried powder and nothing else. No leaflet, no instructions, no dosing chart. A research storefront that ships a protocol has contradicted the research-use basis its sale depends on, and that contradiction is a reason to be more careful rather than less. The rest of the vetting sequence, including stock location and the route back if a batch is wrong, is on our supplier checklist.

The last box-opening check is the one most people skip because they are pleased the parcel arrived. Photograph the vial and the label, match the lot number to the certificate, and keep both. If a problem emerges later, that is the entire evidence base you will have.

The table below is how we read an NAD+ product page. The third column is the useful one: it is not what a thin listing omits, it is what it puts there instead, because the substitution is usually deliberate and always tells you something.

NAD+ for sale is not a scarce phrase. Listings are everywhere, they are mostly legal as research-material sales, and the price spread across them is enormous. What varies is whether anybody upstream treated the powder as something destined for a sterile preparation, and only two lines on a product page speak to that: the grade statement and the endotoxin result.

If a listing has both, you can make a decision. If it has neither, the purity percentage on the front is decoration. Ask for both in writing before you buy, and treat a non-answer as the answer. The vendor that gets defensive about a routine sourcing question has just saved you the postage.